Yang Ronghui, Fu Di, Liao Aijun
Department of Blood Transfusion, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Front Immunol. 2025 Jan 31;16:1529184. doi: 10.3389/fimmu.2025.1529184. eCollection 2025.
The domain of cancer treatment has persistently been confronted with significant challenges, including those associated with recurrence and drug resistance. The complement system, which serves as the foundation of the innate immune system, exhibits intricate and nuanced dual characteristics in the evolution of tumors. On the one hand, the complement system has the capacity to directly inhibit cancer cell proliferation via specific pathways, thereby exerting a beneficial anti-tumor effect. Conversely, the complement system can also facilitate the establishment of an immune escape barrier for cancer cells through non-complement-mediated mechanisms, thereby protecting them from eradication. Concurrently, the complement system can also be implicated in the emergence of drug resistance through a multitude of complex mechanisms, directly or indirectly reducing the efficacy of therapeutic interventions and facilitating the progression of cancer. This paper analyses the role of the complement system in tumors and reviews recent research advances in the mechanisms of tumor immune tolerance and drug resistance.
癌症治疗领域一直面临着重大挑战,包括与复发和耐药性相关的挑战。补体系统作为固有免疫系统的基础,在肿瘤的发展过程中表现出复杂而微妙的双重特性。一方面,补体系统能够通过特定途径直接抑制癌细胞增殖,从而发挥有益的抗肿瘤作用。相反,补体系统也可以通过非补体介导的机制促进癌细胞免疫逃逸屏障的建立,从而保护它们不被根除。同时,补体系统还可能通过多种复杂机制参与耐药性的出现,直接或间接降低治疗干预的效果并促进癌症进展。本文分析了补体系统在肿瘤中的作用,并综述了肿瘤免疫耐受和耐药性机制的最新研究进展。